1. Home
  2. NMRA vs EVBN Comparison

NMRA vs EVBN Comparison

Compare NMRA & EVBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • EVBN
  • Stock Information
  • Founded
  • NMRA 2019
  • EVBN 1920
  • Country
  • NMRA United States
  • EVBN United States
  • Employees
  • NMRA N/A
  • EVBN N/A
  • Industry
  • NMRA
  • EVBN Major Banks
  • Sector
  • NMRA
  • EVBN Finance
  • Exchange
  • NMRA Nasdaq
  • EVBN Nasdaq
  • Market Cap
  • NMRA 287.6M
  • EVBN 231.8M
  • IPO Year
  • NMRA 2023
  • EVBN N/A
  • Fundamental
  • Price
  • NMRA $1.80
  • EVBN $42.54
  • Analyst Decision
  • NMRA Strong Buy
  • EVBN Hold
  • Analyst Count
  • NMRA 6
  • EVBN 2
  • Target Price
  • NMRA $20.67
  • EVBN $36.25
  • AVG Volume (30 Days)
  • NMRA 2.0M
  • EVBN 22.9K
  • Earning Date
  • NMRA 03-06-2025
  • EVBN 02-04-2025
  • Dividend Yield
  • NMRA N/A
  • EVBN 3.10%
  • EPS Growth
  • NMRA N/A
  • EVBN N/A
  • EPS
  • NMRA N/A
  • EVBN 2.16
  • Revenue
  • NMRA N/A
  • EVBN $66,970,000.00
  • Revenue This Year
  • NMRA N/A
  • EVBN N/A
  • Revenue Next Year
  • NMRA N/A
  • EVBN N/A
  • P/E Ratio
  • NMRA N/A
  • EVBN $19.72
  • Revenue Growth
  • NMRA N/A
  • EVBN N/A
  • 52 Week Low
  • NMRA $1.60
  • EVBN $24.07
  • 52 Week High
  • NMRA $21.00
  • EVBN $46.21
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 27.76
  • EVBN 42.98
  • Support Level
  • NMRA $1.61
  • EVBN $43.37
  • Resistance Level
  • NMRA $1.80
  • EVBN $44.37
  • Average True Range (ATR)
  • NMRA 0.11
  • EVBN 0.78
  • MACD
  • NMRA 0.23
  • EVBN -0.11
  • Stochastic Oscillator
  • NMRA 51.28
  • EVBN 19.08

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

About EVBN Evans Bancorp Inc.

Evans Bancorp Inc is a financial holding company. Through its subsidiaries, it provides various banking services to consumers and commercial customers in the USA. The firm operates in two segments, Banking Activities and Insurance Agency Activities. The banking business segment includes both commercial and consumer banking services, including lending and depository services and offering non-deposit investment products, such as annuities and mutual funds. The insurance agency segment includes the activities of selling various premium-based insurance policies on a commission basis, including business and personal insurance, employee benefits, surety bonds, risk management, life, disability and long-term care coverage, and providing claims adjusting services to various insurance companies.

Share on Social Networks: